Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

NCT04307797 on ClinicalTrials.gov · last registry update 2024-09-19

A small phase 4 — 10 participants, against a typical 75. The sponsor logged completion for 7 October 2022. Primary outcome, as filed: Part A - Myocardial glucose uptake. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Sponsor type: Other
Enrollment: 10
Started: 2022-01-18
Primary completion: 2022-10-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Part A - Myocardial glucose uptake

Conditions studied

Type 2 Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.